<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35301101</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-3511</ISSN><JournalIssue CitedMedium="Internet"><Volume>118</Volume><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases</Title><ISOAbbreviation>Int J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Assessing the impact of COVID-19 at 1-year using the SF-12 questionnaire: Data from the Anticipate longitudinal cohort study.</ArticleTitle><Pagination><StartPage>236</StartPage><EndPage>243</EndPage><MedlinePgn>236-243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijid.2022.03.013</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1201-9712(22)00152-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few studies to date have explored the health-related quality of life (HRQoL) in patients with long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Anticipate Study is a prospective single-centre observational cohort study. Hospitalised and nonhospitalised patients were seen at a dedicated post-COVID clinic at a 2-4 month (Timepoint 1) and 7-14 month follow-up (Timepoint 2). The main objectives of this study are to assess the longitudinal impact of COVID-19 in patients using the 12-item Short Form Survey (SF-12) score, a health-related quality of life tool, and to identify predictors of developing post-COVID-19 syndrome (PoCS). In addition, we aimed to describe symptomatology and identify predictors of PoCS at 1-year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 155 patients were enrolled, 105 (68%) were female aged 43.3 (31-52) years. In total 149 (96%) and 94 (61%) patients completed follow-up at median 96 (76-118) days and 364 (303-398) days. The overall cohort had significantly reduced physical composite score (PCS) of the SF-12 (45.39 [10.58] vs 50 [10], p&#xa0;=&#xa0;0.02). Participants with PoCS had significantly lower scores than those without symptoms at 1-year follow-up (37.2 [10.4] v 46.1 [10.9] p &lt;0.001), and scores for these patients did not improve over the 2 Timepoints (PCS 34.95 [10.5] - 37.2 [10.4], p&#xa0;=&#xa0;0.22). Fatigue was the most common symptom. Those with 5 or more symptoms at initial diagnosis had lower PCS and mental composite score (MCS) at 1-year. Predictors of PoCS at 1-year were lower PCS and higher baseline heart rate (HR) at clinic review median 3 months after COVID-19.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Patients with PoCS have lower PCS scores during follow-up, which did not significantly improve up to a 1-year follow-up. Lower PCS scores and higher HR at rest can be used in the weeks after COVID-19 can help predict those at risk of PoCS at 1 year.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>O'Kelly</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland; School of Medicine, University College Dublin, Dublin 4, Ireland. Electronic address: brendan.okelly@ucdconnect.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avramovic</LastName><ForeName>Gordana</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Broughan</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Connolly</LastName><ForeName>Stephen Peter</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotter</LastName><ForeName>Aoife G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland; Centre for Experimental Pathogen Host Research, University College Dublin, Dublin 4, Ireland; School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Walter</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glaspy</LastName><ForeName>Shannon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Woo</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>John S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Infectious Diseases Department, Mater Misericordiae University Hospital, Dublin 7, Ireland; School of Medicine, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Int J Infect Dis</MedlineTA><NlmUniqueID>9610933</NlmUniqueID><ISSNLinking>1201-9712</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Post&#x2013;COVID-19 Syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">SF-12</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>Competing interests The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>18</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35301101</ArticleId><ArticleId IdType="pmc">PMC8920113</ArticleId><ArticleId IdType="doi">10.1016/j.ijid.2022.03.013</ArticleId><ArticleId IdType="pii">S1201-9712(22)00152-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arthur JM, Forrest JC, Boehme KW, Kennedy JL, Owens S, Herzog C, et al. Development of ACE2 autoantibodies after SARS-CoV-2 infection. PloS one. 2021;16(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8415618</ArticleId><ArticleId IdType="pubmed">34478478</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D, Kaphan E, Weber S, Babacci B, Arcani R, Faucher B, et al. Persistent IgG anti-cardiolipin autoantibodies are associated with post-covid syndrome. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8487460</ArticleId><ArticleId IdType="pubmed">34614444</ArticleId></ArticleIdList></Reference><Reference><Citation>Botton J , Dray-Spira R, Baricault B, Drouin J, Bertrand M, Jabagi MJ, et&#xa0;al. Reduced risk of severe COVID-19 in more than 1.4 million elderly people aged 75 years and older vaccinated with mRNA-based vaccines. Vaccine. 2022;40(3):414&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8664658</ArticleId><ArticleId IdType="pubmed">34924220</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. Post-COVID conditions. https://wwwcdcgov/coronavirus/2019-ncov/long-term-effects/indexhtml 2021.</Citation></Reference><Reference><Citation>Department of Health and Social Care (DoHaSC). New research into treatment and diagnosis of long COVID. https://wwwgovuk/government/news/new-research-into-treatment-and-diagnosis-of-long-covid 2021. (Last accessed 28.03.2022).</Citation></Reference><Reference><Citation>Delbressine JM, Machado FVC, Go&#xeb;rtz YMJ, Van Herck M, Meys R, Houben-Wilke S, et al. The Impact of Post-COVID-19 Syndrome on Self-Reported Physical Activity. Int J Environ Res Public Health. 2021;18(11)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8199934</ArticleId><ArticleId IdType="pubmed">34205086</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Kapur S, Alberts J, Badley AD, Decker GA, et&#xa0;al. Multi-organ impairment in low-risk individuals with long COVID. medRxiv 2020:2020.10.14.20212555.</Citation></Reference><Reference><Citation>Gandek B, Ware JE, Aaronson NK, Apolone G, Bjorner JB, Brazier JE, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. Journal of clinical epidemiology. 1998;51(11):1171&#x2013;1178.</Citation><ArticleIdList><ArticleId IdType="pubmed">9817135</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi SK, Warren Salmon J, Zhao SZ, Lambert BL, Gore PR, Conrad K. Psychometric evaluation of the 12-item short-form health survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials. Clinical Therapeutics. 2001;23(7):1080&#x2013;1098.</Citation><ArticleIdList><ArticleId IdType="pubmed">11519772</ArticleId></ArticleIdList></Reference><Reference><Citation>Han C, Pulling CC, Telke SE. Huppler Hullsiek K, for the Terry Beirn Community Programs for Clinical Research on A. Assessing the utility of five domains in SF-12 Health Status Questionnaire in an AIDS clinical trial. AIDS (London, England) 2002;16(3)</Citation><ArticleIdList><ArticleId IdType="pubmed">11834955</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet (London, England) 2021;397(10270):220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson JA, Coons SJ. Comparison of the EQ-5D and SF-12 in an adult US sample. Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation. 1998;7(2):155&#x2013;166.</Citation><ArticleIdList><ArticleId IdType="pubmed">9523497</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacson E, Xu J, Lin S-F, Dean SG, Lazarus JM, Hakim RM. A Comparison of SF-36 and SF-12 Composite Scores and Subsequent Hospitalization and Mortality Risks in Long-Term Dialysis Patients. Clinical Journal of the American Society of Nephrology. 2010;5(2):252&#x2013;260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2827595</ArticleId><ArticleId IdType="pubmed">20019120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim LLY, Fisher JD. Use of the 12-item Short-Form (SF-12) Health Survey in an Australian heart and stroke population. Quality of Life Research. 1999;8(1):1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10457733</ArticleId></ArticleIdList></Reference><Reference><Citation>Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 2021;4(2) -e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021;11(1):16144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nature Medicine. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen NN, Hoang VT, Dao TL, Meddeb L, Lagier J-C, Million M, et al. Long-term persistence of symptoms of dyspnoea in COVID-19 patients. International Journal of Infectious Diseases. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627107</ArticleId><ArticleId IdType="pubmed">34848374</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE Copyright &#xa9; 2020; 2020.</Citation></Reference><Reference><Citation>NIH. NIH launches new initiative to study &#x201c;Long COVID&#x201d;. https://wwwnihgov/about-nih/who-we-are/nih-director/statements/nih-launches-new-initiative-study-long-covid 2021.</Citation></Reference><Reference><Citation>See&#xdf;le J, Waterboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dowds J, O'Brien K, Sheill G, Dyer AH, O'Kelly B, et al. Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Annals of the American Thoracic Society. 2021;18(6):997&#x2013;1003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456724</ArticleId><ArticleId IdType="pubmed">33413026</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Jones K, Dunne J, Mooney A, Gaffney F, et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PloS one. 2020;15(11) -e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7652254</ArticleId><ArticleId IdType="pubmed">33166287</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaes AW, Go&#xeb;rtz YMJ, Van Herck M, Machado FVC, Meys R, Delbressine JM, et al. Recovery from COVID-19: a sprint or marathon? 6&#x2005;months follow-up data of online long COVID-19 support group members. ERJ Open Research. 2021:00141&#x2013;02021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8012818</ArticleId><ArticleId IdType="pubmed">34041295</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, de Mol M, Hoefman E, van Etten RW, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respiratory medicine. 2021;176</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7701891</ArticleId><ArticleId IdType="pubmed">33302142</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Herck M, Go&#xeb;rtz YMJ, Houben-Wilke S, Machado FVC, Meys R, Delbressine JM, et al. Severe Fatigue in Long COVID: Web-Based Quantitative Follow-up Study in Members of Online Long COVID Support Groups. Journal of medical Internet research. 2021;23(9):e30274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8457337</ArticleId><ArticleId IdType="pubmed">34494964</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlake JH, Wesselius S, van Genderen ME, van Bommel J, Boxma-de Klerk B, Wils EJ. Psychological distress and health-related quality of life in patients after hospitalization during the COVID-19 pandemic: A single-center, observational study. PloS one. 2021;16(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8357130</ArticleId><ArticleId IdType="pubmed">34379644</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware J, Jr., Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Medical care. 1996;34(3):220&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">8628042</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstock LB, Brook JB, Walters AS, Goris A, Afrin LB, Molderings GJ. Mast cell activation symptoms are prevalent in Long-COVID. International Journal of Infectious Diseases. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8459548</ArticleId><ArticleId IdType="pubmed">34563706</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker M EJ, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, Ward H, Elliott P. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. Imperial College London. 2021 https://spiral.imperial.ac.uk/handle/10044/1/89844</Citation></Reference><Reference><Citation>WHO. Post COVID-19 condition (Long COVID). https://wwwwhoint/srilanka/news/detail/16-10-2021-post-covid-19-condition 2021.</Citation></Reference><Reference><Citation>WHO. WHO Coronavirus (COVID-19) Dashboard 2022. https://covid19whoint/2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>